Physician profile
David H Eilbert
NPI 1225114358
$2,006.69
in general payments reported to CMS, 2019-2025
15 companies · $511 in 2025
The $511 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $64.20 · 2021: $232 · 2022: $376 · 2023: $483 · 2024: $229 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $253.56 | 2024-2025 | Infuse, Miebo |
| Horizon Therapeutics Plc | $247.04 | 2023 | Tepezza |
| Lkc Technologies, INC. | $246.23 | 2023-2025 | |
| Ocular Therapeutix, INC. | $150.00 | 2025 | Dextenza |
| Genzyme Corporation | $131.40 | 2022 | |
| Abbvie INC. | $124.59 | 2022 | |
| Oyster Point Pharma, INC. | $120.30 | 2023 | Tyrvaya |
| Dompe US, INC. | $120.06 | 2022 | |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Amgen INC. | $117.68 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $113.95 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.31 | 2019 | |
| Coopervision INC. | $87.99 | 2024 | Misight Contact Lens |
| Visioneering Technologies, INC. | $50.13 | 2020 | |
| Alcon Vision LLC | $25.06 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.